An increased risk of both venous and arterial thromboembolism was noted in reports from SARS-CoV-2-infected patients in China and has been confirmed in autopsy findings from patients who experienced sudden death. Myeloproliferative Neoplasms (MPNs), which encompass polycythemia vera, essential thrombocythemia and primary myelofibrosis, are thrombophilic disorders with a natural propensity to thrombosis that is fuelled by the intrinsic activation of inflammatory cytokines. It therefore follows that an underlying diagnosis of MPN may increase the risk of worse clinical outcomes and death during periods of active Covid-19 disease. This ambispective, observational study aims to elucidate the key factors which affect the clinical course of patients with MPN who develop Covid-19 disease.
This is an European multicenter observational study that will include around 550 MPN patients
with a confirmed diagnosis of Covid-19 will be followed for at least one month. Detailed
information on the clinical characteristics of these patients and their disease outcomes will
be retrospectively and prospectively collected in a specific eCRF, including MPN
characteristics, treatment and comorbidities pre-Covid-19, time of Covid-19 diagnosis,
drugs/device used for the treatment of Covid-19, any change in MPN therapy, antithrombotic
prophylaxis employed during the period of infection and - for hospitalised patients only -
key blood and laboratory parameters. A particular focus will be on exploring final outcomes
for patients in this study, most notably the incidence of fatal and non-fatal thrombotic
events. Statistical analyses will also be performed looking for any independent factors that
can significantly predict patient outcomes after Covid-19 diagnosis.
Ultimately, this project will provide important insights into disease severity and
progression in patients with MPN and Covid-19 and uncover the key clinical factors which
drive outcomes and mortality. Results may help clinicians better understand how patient
characteristics and management decisions can impact on disease trajectory when MPN and
Covid-19 collide.
Inclusion Criteria:
- Age > 18 years
- Confirmed diagnosed of MPN according to WHO criteria
- Diagnosis of COVID-19 based by the positivity of oropharyngeal swab performed between
15 February 2020 up to 15 February 2022
- Signed informed consent
Exclusion Criteria:
- None
New York-Presbyterian/Weill Cornell Medical Center
New York, New York, United States
National Specialised Hospital for Active Treatment of Hematological Diseases
Sofia, Bulgaria
University hospital Dubrava-School of Medicine University of Zagreb
Zagreb, Croatia
Hopital Saint-Louis
Paris, France
University Hospital Halle, Department of Hematology/Oncology
Halle, Saale, Germany
University Medical Center RWTH
Aachen, Germany
University Medicine Greifswald - Hematology, Oncology, Stem Cell Transplantation and Palliative Care
Greifswald, Germany
University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center
Minden, Germany
Ospedale San Gerardo di Monza
Monza, Monza Brianza, Italy
A.S.O. SS. Antonio e Biagio e C.Arrigo di Alessandria
Alessandria, Italy
ASST-Papa Giovanni XXIII
Bergamo, Italy
Policlinico S.Orsola-Malpighi
Bologna, Italy
ASST-Spedali Civili
Brescia, Italy
AOU Ospedale Careggi
Firenze, Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milano, Italy
IRCCS Ospedale San Raffaele
Milano, Italy
Azienda Ospedaliero Universitaria Maggiore della Carità
Novara, Italy
IRCCS Policlinico San Matteo
Pavia, Italy
Policlinico Universitario Fondazione Agostino Gemelli
Roma, Italy
A.O.U. Città della Salute e della Scienza di Torino
Torino, Italy
Ospedale Policlinico "G.B. Rossi" Borgo Roma
Verona, Italy
Ospedale San Bortolo
Vicenza, Italy
Sobas Wroclaw Medical University ·
Wrocław, Poland
Hospital Clínic De Barcelona
Barcelona, Barcellona, Spain
Hospital del Mar
Barcelona, Barcellona, Spain
Institut Català d' Oncologia - Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain
ICO L'Hospitalet - Hospital Moisès Broggi
Sant Joan Despí, Barcelona, Spain
Hospital Universitario Príncipe de Asturias
Alcalá De Henares, Madrid, Spain
Hospital General de La Palma
Breña Alta, Santa Cruz De Tenerife, Spain
Servicio de Hematología Hospital General Universitario de Albacete
Albacete, Spain
Hospital General de Elche
Alicante, Spain
Hospital Vall d'Hebron
Barcelona, Spain
Hospital Universitario de Burgos
Burgos, Spain
ICO Girona Hospital Josep Trueta Servei d'hematologia
Girona, Spain
FEA Hematología Hospital Universitario de Móstoles
Madrid, Spain
Hospital 12 de octubre
Madrid, Spain
Hospital Clínico San Carlos
Madrid, Spain
Hospital Gregorio Marañón
Madrid, Spain
Hospital Moncloa
Madrid, Spain
Hospital Ramón y Cajal
Madrid, Spain
Hospital Universitario Infanta Leonor
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Clínico Universitario
Valencia, Spain
Guy's and St. Thomas' NHS Foundation Trust.
London, United Kingdom
Francesca Fenili
0352678926
ffenili@fondazionefrom.it
Alessandra Carobbio, BioStat
acarobbio@fondazionefrom.it
Tiziano Barbui, Prof, Study Chair
Fondazione per la Ricerca Ospedale di Bergamo